These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 18278976)

  • 21. Impact of orally disintegrating olanzapine on use of intramuscular antipsychotics, seclusion, and restraint in an acute inpatient psychiatric setting.
    Simpson JR; Thompson CR; Beckson M
    J Clin Psychopharmacol; 2006 Jun; 26(3):333-5. PubMed ID: 16702903
    [No Abstract]   [Full Text] [Related]  

  • 22. Best clinical practice with ziprasidone IM: update after 2 years of experience.
    Zimbroff DL; Allen MH; Battaglia J; Citrome L; Fishkind A; Francis A; Herr DL; Hughes D; Martel M; Preval H; Ross R
    CNS Spectr; 2005 Sep; 10(9):1-15. PubMed ID: 16247923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new clinical protocol for the pharmacological management of acute behavioural disturbance.
    Emmerson B; Moudgil V; Woodbridge A; Burrows D; Kingswell B; Kubler P; McMahon K
    Australas Psychiatry; 2011 Oct; 19(5):406-9. PubMed ID: 21995354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
    Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
    Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atypical antipsychotic medications in the psychiatric emergency service.
    Currier GW
    J Clin Psychiatry; 2000; 61 Suppl 14():21-6. PubMed ID: 11154013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
    Kohen I; Preval H; Southard R; Francis A
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of acute agitation in psychotic disorders.
    Mohr P; Pecenák J; Svestka J; Swingler D; Treuer T
    Neuro Endocrinol Lett; 2005 Aug; 26(4):327-35. PubMed ID: 16136016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New treatments for agitation.
    Citrome L
    Psychiatr Q; 2004; 75(3):197-213. PubMed ID: 15335224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological treatment of psychotic agitation.
    Currier GW; Trenton A
    CNS Drugs; 2002; 16(4):219-28. PubMed ID: 11945106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective analysis of intramuscular haloperidol and intramuscular olanzapine in the treatment of agitation in drug- and alcohol-using patients.
    MacDonald K; Wilson MP; Minassian A; Vilke GM; Perez R; Cobb P; Tallian K; Becker O; Feifel D
    Gen Hosp Psychiatry; 2010; 32(4):443-5. PubMed ID: 20633750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Managing the agitated psychotic patient: a reappraisal of the evidence.
    Allen MH
    J Clin Psychiatry; 2000; 61 Suppl 14():11-20. PubMed ID: 11154012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of the Agitated Patient.
    Wolfe C; McCoin N
    Emerg Med Clin North Am; 2024 Feb; 42(1):13-29. PubMed ID: 37977745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.
    San L; Estrada G; Oudovenko N; Vieta E
    BMC Psychiatry; 2017 Apr; 17(1):126. PubMed ID: 28376877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The comparative efficacy of intramuscular antipsychotics for the management of acute agitation.
    Bosanac P; Hollander Y; Castle D
    Australas Psychiatry; 2013 Dec; 21(6):554-62. PubMed ID: 23996795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Approach to the Agitated Emergency Department Patient.
    Gottlieb M; Long B; Koyfman A
    J Emerg Med; 2018 Apr; 54(4):447-457. PubMed ID: 29395692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological management of agitation in emergency settings.
    Yildiz A; Sachs GS; Turgay A
    Emerg Med J; 2003 Jul; 20(4):339-46. PubMed ID: 12835344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.
    Suzuki H; Gen K; Takahashi Y
    Hum Psychopharmacol; 2014 Jan; 29(1):83-8. PubMed ID: 24424709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia.
    Brook S
    J Clin Psychiatry; 2003; 64 Suppl 19():13-8. PubMed ID: 14728085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological management of the agitated pediatric patient.
    Adimando AJ; Poncin YB; Baum CR
    Pediatr Emerg Care; 2010 Nov; 26(11):856-60; quiz 861-3. PubMed ID: 21057285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia.
    Battaglia J; Houston JP; Ahl J; Meyers AL; Kaiser CJ
    Clin Ther; 2005 Oct; 27(10):1612-8. PubMed ID: 16330297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.